Collaborations Pharmaceuticals, Inc. demonstrates a treatment for CLN1 Batten disease crosses the blood-brain-barrier
rhPPT1 is a recombinant protein used to treat an ultra-rare disease called Batten disease CLN1 for which there is currently no FDA approved treatment available. RALEIGH, NC, UNITED STATES, January 16, 2026 /EINPresswire.com/ -- CLN1 Batten …